Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03434730 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT03434730: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03434730 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03434730, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The aim of the research in this study is to make participants' transplant safer by reducing the risk of developing GVHD and GVHD-related complications by giving participants a dose of the drug tocilizumab in addition to the standard approach for GVHD prevention. Tocilizumab reduces the risk of inflammation by blocking the effect of Interleukin-6, a protein that exists in high levels in the blood when there is inflammation. Participants who receive stem cell transplants have high levels of this protein in their blood early after transplant. Therefore, the goal of this study is to reduce the risk of inflammation after transplant with the addition of Tocilizumab. This could decrease the risk of developing GVHD and GVHD-associated complications.
Interventions
- DRUG Mycophenolate Mofetil
- DRUG Tocilizumab
- DRUG Filgrastim
- DRUG Cyclosporine
- RADIATION Total Body Irradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2025-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03434730
The ClinicalTrials.gov registry entry for NCT03434730 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Mycophenolate Mofetil is the first listed.
NCT03434730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03434730 about?
NCT03434730 is a clinical study titled "Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation". The aim of the research in this study is to make participants' transplant safer by reducing the risk of developing GVHD and GVHD-related complications by giving participants a dose of the drug tocilizumab in addition to the standard approach for GVHD prevention. Tocilizumab reduces the risk of infla...
What is the current status of trial NCT03434730?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2018-02-07. Estimated completion is 2025-04-18.
What interventions are being tested in trial NCT03434730?
The interventions under investigation include: Mycophenolate Mofetil (DRUG), Tocilizumab (DRUG), Filgrastim (DRUG), Cyclosporine (DRUG), Total Body Irradiation (RADIATION).
Who is sponsoring clinical trial NCT03434730?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.